<p>GlaxoSmithKline on Thursday said that a pre-clinical analysis of the antibody-based Covid-19 therapy it is developing with US partner Vir has indicated that the drug also works against the new Omicron variant.</p>.<p>Further tests will be carried out on the sotrovimab therapy to firm up the results, GSK said in a statement.</p>.<p><strong>Watch the latest DH Videos here:</strong></p>
<p>GlaxoSmithKline on Thursday said that a pre-clinical analysis of the antibody-based Covid-19 therapy it is developing with US partner Vir has indicated that the drug also works against the new Omicron variant.</p>.<p>Further tests will be carried out on the sotrovimab therapy to firm up the results, GSK said in a statement.</p>.<p><strong>Watch the latest DH Videos here:</strong></p>